These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18031187)

  • 1. Interferon alfacon-1: a novel interferon for the treatment of chronic hepatitis C.
    Alberti A
    BioDrugs; 1999 Nov; 12(5):343-57. PubMed ID: 18031187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.
    Melian EB; Plosker GL
    Drugs; 2001; 61(11):1661-91. PubMed ID: 11577799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus interferon: a novel interferon for the treatment of hepatitis C.
    Heathcote J
    J Viral Hepat; 1998 Sep; 5 Suppl 1():13-8. PubMed ID: 9795924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment.
    Malaguarnera M; Pistone G; Neri S; Romano M; Brogna A; Musumeci S
    BioDrugs; 2004; 18(6):407-13. PubMed ID: 15571424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group.
    Jensen DM; Krawitt EL; Keeffe EB; Hollinger FB; James SP; Mullen K; Everson GT; Hoefs JC; Fromm H; Black M; Foust RT; Pimstone NR; Heathcote EJ; Albert D
    Am J Gastroenterol; 1999 Dec; 94(12):3583-8. PubMed ID: 10606323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ; Perry CM
    Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group.
    Heathcote EJ; James S; Mullen KD; Hauser SC; Rosenblate H; Albert DG
    Hepatology; 1999 Aug; 30(2):562-6. PubMed ID: 10421669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label trial of consensus interferon 15 µg in the treatment of Chinese patients with chronic hepatitis C.
    Hwang S; Lee S; Chu C; Lu R; Chang F
    Hepatol Res; 2001 Mar; 19(3):284-293. PubMed ID: 11251311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
    Bacon BR; Shiffman ML; Mendes F; Ghalib R; Hassanein T; Morelli G; Joshi S; Rothstein K; Kwo P; Gitlin N
    Hepatology; 2009 Jun; 49(6):1838-46. PubMed ID: 19291790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
    Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
    J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group.
    Lee WM; Reddy KR; Tong MJ; Black M; van Leeuwen DJ; Hollinger FB; Mullen KD; Pimstone N; Albert D; Gardner S
    Hepatology; 1998 Nov; 28(5):1411-5. PubMed ID: 9794929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
    Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
    Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of interferon monotherapy in the treatment of relapsers and nonresponders with chronic hepatitis C infection.
    Brass CA
    Clin Ther; 1998; 20(3):388-97. PubMed ID: 9663356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C: a multicentre, randomised, controlled study.
    Barbaro G; Grisorio B; Fruttaldo L; Bacca D; Babudieri S; Torre D; Francavilla R; Rizzo G; Belloni G; Lucchini A; Annese M; Matarazzo F; Hazra C; Barbarini G
    BioDrugs; 2003; 17(6):433-9. PubMed ID: 14614766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
    Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.